NCT05891847View on ClinicalTrials.gov

Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia

Active, not recruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

March 20, 2026

Study Completion Date

March 20, 2026

Conditions

Neurofibroma

Trial Locations (5)

123112

Research Site, Moscow

Unknown

Research Site, Moscow

Research Site, Novosibirsk

Research Site, Saint Petersburg

Research Site, Yekaterinburg

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY